Giovanna Tosato

List of Publications by Year in descending order

172 papers	11,429 citations	19657 61 h-index	30922 102 g-index
175 all docs	175 docs citations	175 times ranked	11046 citing authors

#	Article	IF	Citations
1	Reusable Single Cell for Iterative Epigenomic Analyses. Journal of Visualized Experiments, 2022, , .	0.3	0
2	Inactivation of axon guidance molecule netrin-1 in human colorectal cancer by an epigenetic mechanism. Biochemical and Biophysical Research Communications, 2022, 611, 146-150.	2.1	6
3	Antisense transcription from lentiviral gene targeting linked to an integrated stress response in colorectal cancer cells. Molecular Therapy - Nucleic Acids, 2022, 28, 877-891.	5.1	2
4	Iterative epigenomic analyses in the same single cell. Genome Research, 2021, 31, 1819-1830.	5.5	3
5	Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth. EMBO Molecular Medicine, 2021, 13, e14089.	6.9	13
6	Bone marrow niches in myelodysplastic syndromes. , 2021, 7, .		1
7	Viral interleukin-6 encoded by an oncogenic virus promotes angiogenesis and cellular transformation by enhancing STAT3-mediated epigenetic silencing of caveolin 1. Oncogene, 2020, 39, 4603-4618.	5.9	22
8	Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection. Cells, 2020, 9, 1583.	4.1	65
9	DLC1 deficiency and YAP signaling drive endothelial cell contact inhibition of growth and tumorigenesis. Oncogene, 2019, 38, 7046-7059.	5.9	13
10	Identification of Eph receptor signaling as a regulator of autophagy and a therapeutic target in colorectal carcinoma. Molecular Oncology, 2019, 13, 2441-2459.	4.6	11
11	A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma. Clinical Cancer Research, 2019, 25, 4238-4247.	7.0	17
12	Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression. Journal of the National Cancer Institute, 2018, 110, 390-399.	6.3	13
13	Novel insights into endothelial cell malignancies. Oncotarget, 2018, 9, 37468-37470.	1.8	4
14	Primary Effusion Lymphoma. , 2018, , 1749-1755.		0
15	Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas. Journal of the National Cancer Institute, 2017, 109, .	6.3	9
16	Ephrin ligands and Eph receptors contribution to hematopoiesis. Cellular and Molecular Life Sciences, 2017, 74, 3377-3394.	5.4	14
17	Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration. International Journal of Cancer, 2017, 140, 1597-1608.	5.1	14
18	Characterization of Semaphorin 6A-Mediated Effects on Angiogenesis Through Regulation of VEGF Signaling. Methods in Molecular Biology, 2017, 1493, 345-361.	0.9	1

#	Article	IF	Citations
19	EphrinB2 regulates the emergence of a hemogenic endothelium from the aorta. Scientific Reports, 2016, 6, 27195.	3.3	20
20	Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling. Science Signaling, 2016, 9, ra28.	3.6	44
21	Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). Clinical Infectious Diseases, 2016, 62, 730-738.	5.8	135
22	Induction of Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interleukin-6 by X-Box Binding Protein 1. Journal of Virology, 2016, 90, 368-378.	3.4	26
23	Sinusoidal ephrin receptor EPHB4 controls hematopoietic progenitor cell mobilization from bone marrow. Journal of Clinical Investigation, 2016, 126, 4554-4568.	8.2	35
24	EphrinB2 controls vessel pruning through STAT1-JNK3 signalling. Nature Communications, 2015, 6, 6576.	12.8	54
25	Notch and TGFÎ². OncoImmunology, 2014, 3, e29029.	4.6	3
26	Contribution of Viral Mimics of Cellular Genes to KSHV Infection and Disease. Viruses, 2014, 6, 3472-3486.	3.3	7
27	Investigation of the interactions between the EphB2 receptor and SNEW peptide variants. Growth Factors, 2014, 32, 236-246.	1.7	10
28	Tumor-Infiltrating Myeloid Cells Activate Dll4/Notch/TGF-Î² Signaling to Drive Malignant Progression. Cancer Research, 2014, 74, 2038-2049.	0.9	35
29	Primary Effusion Lymphoma. , 2014, , 195-205.		0
30	Human herpesvirus 8+ polyclonal <scp>I</scp>g<scp>M</scp>Î» <scp>B</scp>â€cell lymphocytosis mimicking plasmablastic leukemia/lymphoma in <scp>HIV</scp>â€infected patients. European Journal of Haematology, 2013, 91, 497-503.	2.2	18
31	Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood, 2013, 122, 4189-4198.	1.4	141
32	Attenuation of Eph Receptor Kinase Activation in Cancer Cells by Coexpressed Ephrin Ligands. PLoS ONE, 2013, 8, e81445.	2.5	47
33	Primary Effusion Lymphoma. , 2013, , 1-7.		0
34	Granulocyte Infiltration and Expression of the Pro-angiogenic Bv8 Protein in Experimental EL4 and Lewis Lung Carcinoma Tumors. Cureus, 2013, 5, 82.	0.5	1
35	Phase I/II study of the safety, pharmacokinetics, and efficacy of pomalidomide in the treatment of Kaposi sarcoma in individuals with or without HIV.. Journal of Clinical Oncology, 2013, 31, TPS10595-TPS10595.	1.6	0
36	Kaposi Sarcoma Herpesvirus Promotes Endothelial-to-Mesenchymal Transition through Notch-Dependent Signaling. Cancer Research, 2012, 72, 1157-1169.	0.9	96

#	Article	IF	Citations
37	Essential Roles of EphB Receptors and EphrinB Ligands in Endothelial Cell Function and Angiogenesis. Advances in Cancer Research, 2012, 114, 21-57.	5.0	118
38	MicroRNA126 contributes to granulocyte colony-stimulating factor-induced hematopoietic progenitor cell mobilization by reducing the expression of vascular cell adhesion molecule 1. Haematologica, 2012, 97, 818-826.	3.5	55
39	HHV-8â€“encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood, 2012, 119, 5173-5181.	1.4	110
40	Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. Blood, 2012, 120, 4104-4115.	1.4	84
41	Adult human circulating CD34â^Linâ^CD45â^CD133â^ cells can differentiate into hematopoietic and endothelial cells. Blood, 2011, 118, 2105-2115.	1.4	24
42	High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood, 2011, 117, 6977-6986.	1.4	149
43	NF-ÎºB Activation Stimulates Transcription and Replication of Retrovirus XMRV in Human B-Lineage and Prostate Carcinoma Cells. Journal of Virology, 2011, 85, 3179-3186.	3.4	12
44	Viral Interleukin-6: Role in Kaposi's Sarcoma-Associated Herpesvirusâ€“Associated Malignancies. Journal of Interferon and Cytokine Research, 2011, 31, 791-801.	1.2	59
45	PEGylation Potentiates the Effectiveness of an Antagonistic Peptide That Targets the EphB4 Receptor with Nanomolar Affinity. PLoS ONE, 2011, 6, e28611.	2.5	36
46	Distinct Human and Viral Interleukin-6 Profiles and Other Viral and Immunologic Abnormalities In KSHV-Associated Multicentric Castleman Disease: Relationship with Disease Activity and Individual Disease Manifestations. Blood, 2011, 118, 1573-1573.	1.4	0
47	The transcription factor Gfi1 regulates G-CSF signaling and neutrophil development through the Ras activator RasGRP1. Blood, 2010, 115, 3970-3979.	1.4	43
48	Oligo-guanosine nucleotide induces neuropilin-1 internalization in endothelial cells and inhibits angiogenesis. Blood, 2010, 116, 3099-3107.	1.4	6
49	Cytosolic Phospholipase A2Â and Cancer: A Role in Tumor Angiogenesis. Journal of the National Cancer Institute, 2010, 102, 1377-1379.	6.3	27
50	An Interleukinâ€6â€“Related Systemic Inflammatory Syndrome in Patients Coâ€Infected with Kaposi Sarcomaâ€“Associated Herpesvirus and HIV but without Multicentric Castleman Disease. Clinical Infectious Diseases, 2010, 51, 350-358.	5.8	266
51	Impaired Recruitment of Grk6 and Î²-Arrestin2 Causes Delayed Internalization and Desensitization of a WHIM Syndrome-Associated CXCR4 Mutant Receptor. PLoS ONE, 2009, 4, e8102.	2.5	55
52	Gene Regulation and Functional Alterations Induced by Kaposi's Sarcoma-Associated Herpesvirus-Encoded ORFK13/vFLIP in Endothelial Cells. Journal of Virology, 2009, 83, 2140-2153.	3.4	35
53	The Tensin-3 Protein, Including its SH2 Domain, Is Phosphorylated by Src and Contributes to Tumorigenesis and Metastasis. Cancer Cell, 2009, 16, 246-258.	16.8	81
54	Regulation of angiogenesis in malignancies associated with Epsteinâ€“Barr virus and Kaposiâ€™s sarcoma-associated herpes virus. Future Microbiology, 2009, 4, 903-917.	2.0	22

#	Article	IF	Citations
55	EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures. Blood, 2009, 114, 1707-1716.	1.4	99
56	Palmitoylation Controls Recycling in Lysosomal Sorting and Trafficking. Traffic, 2008, 9, 1984-1997.	2.7	77
57	Contribution of viral and cellular cytokines to Kaposiâ€™s sarcoma-associated herpesvirus pathogenesis. Journal of Leukocyte Biology, 2008, 84, 994-1000.	3.3	39
58	Regulation of CXCR4 by the Notch Ligand Delta-like 4 in Endothelial Cells. Cancer Research, 2008, 68, 1889-1895.	0.9	54
59	Neuropilin-2: A New Molecular Target for Antiangiogenic and Antitumor Strategies. Journal of the National Cancer Institute, 2008, 100, 81-83.	6.3	9
60	Sulfated polysaccharides identified as inducers of neuropilin-1 internalization and functional inhibition of VEGF165 and semaphorin3A. Blood, 2008, 111, 4126-4136.	1.4	51
61	Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth. Blood, 2008, 112, 1904-1911.	1.4	47
62	Effect of Fibroblast Growth Factor 2 on Stromal Cell-Derived Factor 1 Production by Bone Marrow Stromal Cells and Hematopoiesis. Journal of the National Cancer Institute, 2007, 99, 223-235.	6.3	26
63	Targeting the Tumor Vasculature to Improve the Efficacy of Oncolytic Virus Therapy. Journal of the National Cancer Institute, 2007, 99, 1739-1741.	6.3	10
64	Transcription factor Gfi-1 induced by G-CSF is a negative regulator of CXCR4 in myeloid cells. Blood, 2007, 110, 2276-2285.	1.4	61
65	FGF2 posttranscriptionally down-regulates expression of SDF1 in bone marrow stromal cells through FGFR1 IIIc. Blood, 2007, 109, 1363-1372.	1.4	26
66	Generation of Epsteinâ€Barr Virus (EBV)â€“Immortalized B Cell Lines. Current Protocols in Immunology, 2007, 76, Unit 7.22.	3.6	69
67	Novel Anti-Inflammatory Properties of the Angiogenesis Inhibitor Vasostatin. Journal of Investigative Dermatology, 2007, 127, 65-74.	0.7	26
68	PART IV. Cytokine and Hormone ImmunotherapyTreatment of AIDS-Related Kaposi's Sarcoma with Interleukin-12: Rationale and Preliminary Evidence of Clinical Activity. Critical Reviews in Immunology, 2007, 27, 401-414.	0.5	28
69	Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood, 2006, 107, 931-939.	1.4	327
70	Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. Blood, 2006, 107, 3892-3901.	1.4	74
71	G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood, 2006, 108, 812-820.	1.4	184
72	Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood, 2006, 107, 4650-4657.	1.4	113

#	Article	IF	Citations
73	EphB2 and EphB4 receptors forward signaling promotes SDF-1â€“induced endothelial cell chemotaxis and branching remodeling. Blood, 2006, 108, 2914-2922.	1.4	80
74	Conflicting Results from Clinical Observations and Murine Models: What Is the Role of Plasminogen Activators in Tumor Growth?. Journal of the National Cancer Institute, 2006, 98, 726-727.	6.3	1
75	Tumor Cell Populations Differ in Angiogenic Activity: A Model System for Spontaneous Angiogenic Switch Can Tell Us Why. Journal of the National Cancer Institute, 2006, 98, 294-295.	6.3	11
76	Prostaglandin E2promotes degranulation-independent release of MCP-1 from mast cells. Journal of Leukocyte Biology, 2006, 79, 95-104.	3.3	75
77	Therapy Insight: AIDS-related malignanciesâ€”the influence of antiviral therapy on pathogenesis and management. Nature Clinical Practice Oncology, 2005, 2, 406-415.	4.3	57
78	Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood, 2005, 105, 1992-1999.	1.4	109
79	Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1Î± in the circulation. Blood, 2005, 105, 4561-4568.	1.4	93
80	Role of Human Cripto-1 in Tumor Angiogenesis. Journal of the National Cancer Institute, 2005, 97, 132-141.	6.3	76
81	Targeting Coagulation to the Tumor Microvasculature: Perspectives and Therapeutic Implications From Preclinical Studies. Journal of the National Cancer Institute, 2005, 97, 705-707.	6.3	16
82	Lymphatic Regeneration: New Insights From VEGFR-3 Blockade. Journal of the National Cancer Institute, 2005, 97, 2-3.	6.3	13
83	B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood, 2005, 106, 795-802.	1.4	114
84	Mast cellâ€“derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. Journal of Clinical Investigation, 2004, 114, 1317-1325.	8.2	125
85	Evidence for the involvement of SDF-1 and CXCR4 in the disruption of endothelial cell-branching morphogenesis and angiogenesis by TNF-Î± and IFN-Î³. Journal of Leukocyte Biology, 2004, 76, 217-226.	3.3	51
86	Derivation of Endothelial Cells from CD34â^'Umbilical Cord Blood. Stem Cells, 2004, 22, 385-395.	3.2	53
87	Therapeutic options for human herpesvirus-8/Kaposiâ€™s sarcoma-associated herpesvirus-related disorders. Expert Review of Anti-Infective Therapy, 2004, 2, 213-225.	4.4	11
88	Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood, 2004, 103, 301-308.	1.4	130
89	HIV-1 Tat enhances Kaposi sarcomaâ€“associated herpesvirus (KSHV) infectivity. Blood, 2004, 104, 810-814.	1.4	80
90	Differential processing of stromal-derived factor-1Î± and stromal-derived factor-1Î² explains functional diversity. Blood, 2004, 103, 2452-2459.	1.4	192

#	Article	IF	Citations
91	Neoplastic Conditions in the Context of HIV-1 Infection. Current HIV Research, 2004, 2, 343-349.	0.5	38
92	Introduction: Herpesviruses in hematology. Seminars in Hematology, 2003, 40, 105-106.	3.4	0
93	Pathogenesis and manifestations of human herpesvirus-8-associated disorders. Seminars in Hematology, 2003, 40, 143-153.	3.4	21
94	Interferon-Â Is Implicated in the Transcriptional Regulation of Vascular Endothelial Growth Factor. Journal of the National Cancer Institute, 2003, 95, 420-421.	6.3	8
95	A Pilot Study of Cidofovir in Patients with Kaposi Sarcoma. Journal of Infectious Diseases, 2003, 187, 149-153.	4.0	84
96	Serum inactivation contributes to the failure of stromal-derived factor-1 to block HIV-I infection in vivo. Journal of Leukocyte Biology, 2003, 74, 880-888.	3.3	31
97	Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood, 2003, 101, 1535-1542.	1.4	426
98	Selective expression of stromal-derived factor-1 in the capillary vascular endothelium plays a role in Kaposi sarcoma pathogenesis. Blood, 2003, 102, 3900-3905.	1.4	58
99	Viral and Cellular Cytokines as Therapeutic Targets in AIDS-Related Lymphoproliferative Disorders. Current Drug Targets Cardiovascular & Haematological Disorders, 2003, 3, 81-96.	2.0	1
100	Pathogenesis and manifestations of human herpesvirus-8-associated disorders. Seminars in Hematology, 2003, 40, 143-153.	3.4	15
101	Targeted Inhibition of Angiogenic Factors in AIDS-related Disorders. Current Drug Targets Infectious Disorders, 2003, 3, 115-128.	2.1	22
102	Calreticulin and Tumor Suppression. Molecular Biology Intelligence Unit, 2003, , 162-179.	0.2	2
103	Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood, 2002, 99, 2703-2711.	1.4	315
104	Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunology, Immunotherapy, 2002, 51, 358-366.	4.2	38
105	Biological aspects of Epsteinâ€“Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies. Critical Reviews in Oncology/Hematology, 2002, 44, 239-249.	4.4	59
106	Hypoxia induces lytic replication of Kaposi sarcomaâ€“associated herpesvirus. Blood, 2001, 97, 3244-3250.	1.4	220
107	Detection of viral interleukin-6 in Kaposi sarcomaâ€“associated herpesvirusâ€“linked disorders. Blood, 2001, 97, 2173-2176.	1.4	114
108	Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. Blood, 2001, 97, 2526-2527.	1.4	76

#	Article	IF	Citations
109	Receptor engagement by viral interleukin-6 encoded by Kaposi sarcomaâ€“associated herpesvirus. Blood, 2001, 98, 3042-3049.	1.4	68
110	The Angiogenesis Inhibitor Vasostatin does not Impair Wound Healing at Tumor-Inhibiting Doses. Journal of Investigative Dermatology, 2001, 117, 1036-1041.	0.7	49
111	Vascular Endothelial Growth Factor/Vascular Permeability Factor in the Pathogenesis of Primary Effusion Lymphomas. Leukemia and Lymphoma, 2001, 41, 229-237.	1.3	43
112	Macrophage-Derived Chemokine Expression in Classical Hodgkin's Lymphoma: Application of Tissue Microarrays. Modern Pathology, 2001, 14, 1270-1276.	5.5	48
113	Diagnosis of Atypical Cases of Infectious Mononucleosis. Clinical Infectious Diseases, 2001, 33, 83-88.	5.8	107
114	Chemokine Gene Expression and Clonal Analysis of B Cells in Tissues Involved by Lymphoid Interstitial Pneumonitis from HIV-Infected Pediatric Patients. Modern Pathology, 2001, 14, 929-936.	5.5	16
115	Contribution of automated hematology analysis to the detection of apoptosis in peripheral blood lymphocytes. Cytometry, 2000, 42, 209-214.	1.8	11
116	Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas. Blood, 2000, 95, 1109-1110.	1.4	25
117	Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions. Blood, 2000, 96, 1599-1601.	1.4	85
118	Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood, 2000, 96, 1900-1905.	1.4	82
119	Activity of Thalidomide in AIDS-Related Kaposiâ€™s Sarcoma. Journal of Clinical Oncology, 2000, 18, 2593-2602.	1.6	288
120	State-of-the-Art Review: Kaposi's Sarcoma-Associated Herpesvirus-Encoded Interleukin-6. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 137-145.	1.8	41
121	The Role of Chemokines in Hodgkin's Disease. Leukemia and Lymphoma, 2000, 38, 363-371.	1.3	83
122	Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions. Blood, 2000, 96, 1599-1601.	1.4	38
123	Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood, 2000, 96, 1900-1905.	1.4	3
124	Development of EBV-Positive T-cell Lymphoma Following Infection of Peripheral Blood T Cells with EBV. Leukemia and Lymphoma, 1999, 34, 603-607.	1.3	11
125	Role of Vascular Endothelial Growth Factor/Vascular Permeability Factor in the Pathogenesis of Kaposi's Sarcoma-Associated Herpesvirus-Infected Primary Effusion Lymphomas. Blood, 1999, 94, 4247-4254.	1.4	101
126	Calreticulin and Calreticulin Fragments Are Endothelial Cell Inhibitors That Suppress Tumor Growth. Blood, 1999, 94, 2461-2468.	1.4	170

#	Article	IF	Citations
127	Angiogenesis and Hematopoiesis Induced by Kaposiâ€™s Sarcoma-Associated Herpesvirus-Encoded Interleukin-6. Blood, 1999, 93, 4034-4043.	1.4	371
128	Contribution of Natural Killer Cells to Inhibition of Angiogenesis by Interleukin-12. Blood, 1999, 93, 1612-1621.	1.4	174
129	Differential Chemokine Expression in Tissues Involved by Hodgkinâ€™s Disease: Direct Correlation of Eotaxin Expression and Tissue Eosinophilia. Blood, 1999, 93, 2463-2470.	1.4	138
130	Involvement of Interleukin-10 (IL-10) and Viral IL-6 in the Spontaneous Growth of Kaposiâ€™s Sarcoma Herpesvirus-Associated Infected Primary Effusion Lymphoma Cells. Blood, 1999, 94, 2871-2879.	1.4	228
131	Increased Cellâ€Free Viral DNA in Fatal Cases of Chronic Active Epsteinâ€Barr Virus Infection. Clinical Infectious Diseases, 1999, 28, 906-906.	5.8	30
132	Interleukin-18, Interferon-Î³, IP-10, and Mig Expression in Epstein-Barr Virus-Induced Infectious Mononucleosis and Posttransplant Lymphoproliferative Disease. American Journal of Pathology, 1999, 155, 257-265.	3.8	64
133	Angiogenesis and Hematopoiesis Induced by Kaposiâ€™s Sarcoma-Associated Herpesvirus-Encoded Interleukin-6. Blood, 1999, 93, 4034-4043.	1.4	172
134	Involvement of Interleukin-10 (IL-10) and Viral IL-6 in the Spontaneous Growth of Kaposiâ€™s Sarcoma Herpesvirus-Associated Infected Primary Effusion Lymphoma Cells. Blood, 1999, 94, 2871-2879.	1.4	97
135	Contribution of Natural Killer Cells to Inhibition of Angiogenesis by Interleukin-12. Blood, 1999, 93, 1612-1621.	1.4	70
136	Differential Chemokine Expression in Tissues Involved by Hodgkinâ€™s Disease: Direct Correlation of Eotaxin Expression and Tissue Eosinophilia. Blood, 1999, 93, 2463-2470.	1.4	22
137	Role of Vascular Endothelial Growth Factor/Vascular Permeability Factor in the Pathogenesis of Kaposi's Sarcoma-Associated Herpesvirus-Infected Primary Effusion Lymphomas. Blood, 1999, 94, 4247-4254.	1.4	33
138	Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. Seminars in Immunopathology, 1998, 20, 405-423.	4.0	19
139	Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth. Journal of Experimental Medicine, 1998, 188, 2349-2356.	8.5	299
140	EBV-NK Cells Interactions and Lymphoproliferative Disorders. Leukemia and Lymphoma, 1998, 29, 491-498.	1.3	38
141	Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. Journal of Leukocyte Biology, 1998, 64, 384-392.	3.3	125
142	A Syndrome of Peripheral Blood T-Cell Infection With Epstein-Barr Virus (EBV) Followed by EBVâ€“Positive T-Cell Lymphoma. Blood, 1998, 91, 2085-2091.	1.4	101
143	Expression of the Epstein-Barr Virus Protein LMP1 Mediates Tumor Regression In Vivo. Blood, 1998, 91, 2491-2500.	1.4	27
144	Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. Seminars in Immunopathology, 1998, 20, 405-423.	4.0	3

#	Article	IF	Citations
145	A Syndrome of Peripheral Blood T-Cell Infection With Epstein-Barr Virus (EBV) Followed by EBVâ€“Positive T-Cell Lymphoma. Blood, 1998, 91, 2085-2091.	1.4	1
146	Expression of the Epstein-Barr Virus Protein LMP1 Mediates Tumor Regression In Vivo. Blood, 1998, 91, 2491-2500.	1.4	2
147	Viral Interleukinâ€10 in Chronic Active EpsteinâEBarr Virus Infection. Journal of Infectious Diseases, 1997, 176, 254-257.	4.0	78
148	Interleukin-15 Promotes Angiogenesisin Vivo. Biochemical and Biophysical Research Communications, 1997, 233, 231-237.	2.1	110
149	The Role of Mig, the Monokine Induced by Interferon-Î³, and IP-10, the Interferon-Î³â€“Inducible Protein-10, in Tissue Necrosis and Vascular Damage Associated With Epstein-Barr Virus-Positive Lymphoproliferative Disease. Blood, 1997, 90, 4099-4105.	1.4	162
150	Mig, the Monokine Induced By Interferon-Î³, Promotes Tumor Necrosis In Vivo. Blood, 1997, 89, 2635-2643.	1.4	242
151	Infectious mononucleosis as a disease of early childhood in Japan caused by primary EpsteinâEBarr virus infection. Pediatrics International, 1997, 39, 166-171.	0.5	20
152	A Role for the Interferon-Inducible Protein 10 in Inhibition of Angiogenesis by Interleukin-12. Annals of the New York Academy of Sciences, 1996, 795, 158-167.	3.8	109
153	Chronic persistent EpsteinâEBarr virus infection of natural killer cells and B cells associated with granular lymphocytes expansion. British Journal of Haematology, 1996, 95, 116-122.	2.5	31
154	8 Epstein-Barr virus as an agent of haematological disease. Best Practice and Research: Clinical Haematology, 1995, 8, 165-199.	1.1	18
155	Regression of Experimental Human Leukemias and Solid Tumors Induced by Epstein-Barr Virus-Immortalized B Cells. Leukemia and Lymphoma, 1995, 19, 267-276.	1.3	18
156	Human and Viral Interleukin-10 in Acute Epstein-Barr Virus-Induced Infectious Mononucleosis. Journal of Infectious Diseases, 1995, 171, 1347-1350.	4.0	47
157	A Mechanism of T Cell Regulation of Epstein-Barr Virus Latency. Cellular Immunology, 1993, 147, 256-266.	3.0	2
158	Association of Interleukin-6 in the Pathogenesis of Acutely Fatal SIVsmm/PBj-14in Pigtailed Macaques*. AIDS Research and Human Retroviruses, 1993, 9, 1123-1129.	1.1	37
159	IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. International Immunology, 1993, 5, 1599-1608.	4.0	117
160	Heterotransplantation of Human Burkitt’s Lymphoma Cell Lines in Athymic Nude Mice: Tumor-Host Relationships. Pathobiology, 1993, 61, 164-172.	3.8	2
161	Development of Opportunistic Non-Hodgkinï¿½s Lymphomas in Severely Immunosuppressed HIV-Infected Patients Receiving Long-Term Antiretroviral Therapy. , 1992, , 196-206.		0
162	A Merging of Disciplines. Annals of the New York Academy of Sciences, 1989, 557, xv.	3.8	9

#	Article	IF	Citations
163	A Monocyteâ€derived B Cell Growth Factor Is IFNâ€Î²₂/BSFâ€2/ILâ€6^a. Annals of the New York Academy of Sciences, 1989, 557, 181-191.	3.8	5
164	Cell-Mediated Immunity. Clinical Topics in Infectious Disease, 1989, , 100-116.	0.2	1
165	Growth Stimulation and Immunoglobulin (Ig) Secretion in Epstein-Barr Virus (Ebv)-Infected B Cells by Interleukin 6 (IL-6). , 1989, , 227-229.		0
166	The Epstein-Barr Virus and The Immune System. Advances in Cancer Research, 1987, 49, 75-125.	5.0	84
167	Monocytes and a Monocyte Product Regulate Epstein-Barr Virus-Induced B Cell Activation. , 1987, , 379-383.		0
168	Defective Regulation of Epsteinâ€“Barr Virus Infection in Patients with Acquired Immunodeficiency Syndrome (AIDS) or AIDS-Related Disorders. New England Journal of Medicine, 1986, 314, 874-879.	27.0	390
169	Epstein-Barr Virus Infection and Immunoregulation in Man. Advances in Immunology, 1985, 37, 99-149.	2.2	144
170	B-cell-derived interleukin 1 (IL-1)-like factor. Cellular Immunology, 1985, 94, 406-417.	3.0	53
171	B-cell-derived interleukin-1 (IL-1)-like factor. Cellular Immunology, 1985, 94, 418-426.	3.0	41
172	Defective EBV-Specific Suppressor T-Cell Function in Rheumatoid Arthritis. New England Journal of Medicine, 1981, 305, 1238-1243.	27.0	228